Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651)



Status:Recruiting
Conditions:Colorectal Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/17/2019
Start Date:February 16, 2018
End Date:November 26, 2021
Contact:Toll Free Number
Email:Trialsites@merck.com
Phone:1-888-577-8839

Use our guide to learn which trials are right for you!

A Phase 1b Multi-cohort Study of the Combination of Pembrolizumab (MK-3475) Plus Binimetinib Alone or the Combination of Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Participants With Metastatic Colorectal Cancer (KEYNOTE-651)

The purpose of this study is to determine safety and tolerability and to establish a
preliminary recommended Phase 2 dose (RP2D) for the following combinations: pembrolizumab
plus binimetinib (Cohort A), pembrolizumab plus mFOLFOX7 (oxaliplatin 85 mg/m^2; leucovorin
[calcium folinate] 400 mg/m^2; fluorouracil [5-FU] 2400 mg/m^2) (Cohort B), pembrolizumab
plus mFOLFOX7 and binimetinib (Cohort C), pembrolizumab plus FOLFIRI (irinotecan 180 mg/m^2;
leucovorin [calcium folinate]400 mg/m^2; 5-FU 2400 mg/m^2 over 46-48 hours) (Cohort D), and
pembrolizumab plus FOLFIRI and binimetinib (Cohort E).


Inclusion Criteria:

- At least 18 years of age

- Has a histologically-confirmed, unresectable or metastatic (Stage IV American Joint
Committee on Cancer [AJCC seventh edition]) colorectal cancer (CRC)

- Has a locally determined non microsatellite instability high/ proficient mismatch
repair (non-MSI-H/pMMR) tumor status

- Has at least 1 radiologically measurable lesion as defined by RECIST 1.1

- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Has a life expectancy of at least 3 months

- Has the ability to swallow and retain oral medication and not have any clinically
significant gastrointestinal abnormalities that might alter absorption.

- Has adequate organ function

- Male participants must agree to use contraception during the treatment period and for
≥180 days, after the last dose of study treatment and refrain from donating sperm
during this period. Male participants with pregnant partners must agree to use a
condom

- Female participants eligible to participate if not pregnant, not breastfeeding, and is
not a woman of childbearing potential (WOCBP) or is a WOCBP who agrees to follow
contraceptive guidance during the treatment period and for ≥180 days after the last
dose of study treatment

- Participants for Cohort A:

- Has been previously treated with fluoropyrimidine, irinotecan, and oxaliplatin

- Participants for Cohorts B and C:

- Must not have received prior systemic chemotherapy for Stage IV CRC

- Participants for Cohorts D and E:

- Must have been previously treated with 1 line of therapy including a fluoropyrimidine
plus an oxaliplatin-based regimen

- Participants for Cohorts A, C, and E:

- Have a 12-lead electrocardiogram (ECG) and echocardiogram (ECHO) or multigated
acquisition (MUGA) scan performed by the investigator or other qualified person to
evaluate cardiac function prior to enrollment in the study

Exclusion Criteria:

- Is currently participating and receiving study therapy in a study of an
investigational agent or has participated and received study therapy in a study of an
investigational agent or has used an investigational device within 28 days of
administration of MK-3475

- Has had chemotherapy, definitive radiation, or biological cancer therapy within 4
weeks (prior to the first dose of study therapy, or has not recovered to Common
Terminology Criteria for Adverse Events (CTCAE) Gr 1 or better from any AEs that were
due to cancer therapeutics administered more than 4 weeks earlier

- Has history of a second malignancy, unless potentially curative treatment has been
completed with no evidence of malignancy for 2 years

- Has clinically active central nervous system (CNS) metastases and/or carcinomatous
meningitis

- Has a known hypersensitivity, intolerability or contraindication to any component of
study treatment, including premedication

- Has any active infection requiring systemic therapy

- Has a history of (non-infectious) pneumonitis that required steroids or has current
pneumonitis

- Has received prior therapy with compounds targeting programmed death (PD)-1, PD-L1,
PD-L2, or a mitogen-activated protein kinase (MAPK) pathway inhibitor

- Has an autoimmune disease that has required systemic treatment in the past 2 years
with use of disease modifying agents, corticosteroids, or immunosuppressive drugs

- Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any
other form of immunosuppressive therapy within 7 days prior to randomization

- Has known history of human immunodeficiency virus (HIV) infection

- Has a known history of Hepatitis B

- Has received live vaccine within 30 days of the planned start of study therapy

- Has undergone major surgery and has not recovered adequately from any toxicity and/or
complications from the intervention prior to starting study therapy

- Has baseline peripheral neuropathy/paresthesia

- Has any medical, psychiatric, cognitive, or other conditions that may compromise the
participant's ability to understand the participant information, give informed
consent, comply with the study protocol, or complete the study.

- Has symptomatic congestive heart failure (CHF)

- Has a history of acute or chronic pancreatitis

- Has existing uncontrolled arterial hypertension (systolic blood pressure [SBP] ≥150
mmHg or diastolic blood pressure [DBP] ≥100 mmHg) despite appropriate medical therapy

- Has a history of thromboembolic or cerebrovascular events within 6 months prior to
registration

- Has neuromuscular disorders associated with an elevated creatine kinase

- A WOCBP who has a positive urine pregnancy test within 24 hours before the first dose
of study treatment

- Potential Participants for Cohorts A, C or E who are to Receive Binimetinib:

- Has a history of, or current, retinal vein occlusion (RVO) or current risk factors for
RVO

- Has retinal degenerative disease

- Potential Participants for Cohorts A, C, D or E:

- Has a known history of Gilbert's Syndrome

- Potential Participants for Cohorts D or E:

- Has a previous treatment with irinotecan

- Has plans to use, or is using, any herbal medications/supplements or any medications
or foods that are strong inhibitors or inducers of cytochrome P450 3A 4/5 ≤1 week
prior to the start of study treatment
We found this trial at
11
sites
Pittsburgh, Pennsylvania 15232
Phone: 412-623-2677
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
5801 South Ellis Avenue
Chicago, Illinois 60637
 773.702.1234
Phone: 773-702-7763
University of Chicago One of the world's premier academic and research institutions, the University of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
825 Eastlake Ave E
Seattle, Washington 98109
(206) 288-7222
Phone: 206-288-6248
Seattle Cancer Care Alliance Seattle Cancer Care Alliance (SCCA) is a cancer treatment center that...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Aurora, Colorado 80045
Phone: 303-724-3532
?
mi
from
Aurora, CO
Click here to add this to my saved trials
1500 East Duarte Road
Duarte, California 91010
626-256-HOPE (4673)
Phone: 626-471-9200
City of Hope National Medical Center City of Hope is dedicated to making a difference...
?
mi
from
Duarte, CA
Click here to add this to my saved trials
Edmonton, Alberta
Phone: 7804328248
?
mi
from
Edmonton,
Click here to add this to my saved trials
New Brunswick, New Jersey 08903
Phone: 732-235-2465
?
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
333 Cedar Street
New Haven, Connecticut 06520
(203) 785-4095
Phone: 203-785-6661
Yale Cancer Center Yale Cancer Center combines a tradition of innovative cancer treatment and quality...
?
mi
from
New Haven, CT
Click here to add this to my saved trials
Tacoma, Washington 98405
Phone: 253-428-8738
?
mi
from
Tacoma, WA
Click here to add this to my saved trials
Tampa, Florida 33612
Phone: 813-745-2742
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Temple, Texas 76504
Phone: 254-724-3796
?
mi
from
Temple, TX
Click here to add this to my saved trials